Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Lilly stops development of three drugs, including gene therapy
Eli Lilly is dropping the development of three therapies that did not meet expectations, including a gene therapy acquired during…
-
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
Ultragenyx Pharmaceutical’s gene therapy has shown durable improvements in patients with Sanfilippo syndrome Type A (MPS IIIA), a rare neurodegenerative…
-
Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial
Pfizer’s recently acquired weight loss injection has shown to maintain weight loss after a switch from weekly to monthly dosing…
-
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial
Novo Nordisk’s CagriSema has outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight…
-
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Massive Bio and ConcertAI have each introduced artificial intelligence (AI)-based systems aimed at supporting oncology clinical trials at the Summit…
-
Sanofi records win and loss with rare disease drug in Phase III trials
Sanofi’s rare disease drug venglustat has met the primary endpoint in a Phase III trial in Gaucher disease but missed…
-
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ stock has fallen by more than 90% after a Phase III trial of its Ataxia-Telangiectasia (A-T) drug failed…
-
From real to regulatory: why RWD needs trial-grade standards
As the US Food and Drug Administration (FDA) becomes more receptive to the use of real-world data (RWD) in drug…
-
Boehringer Ingelheim’s kidney drug reduces proteinuria by 40% in Phase II trial
Boehringer Ingelheim’s apecotrep has led to a 40% reduction in proteinuria, a key indicator associated with kidney damage, in patients…